1 / 1

Melanoma Therapeutic Studies at University Hospital Heidelberg

Explore ongoing melanoma therapy studies at the NCT center. Contact Dr. Jessica C. Hassel for details on IFN therapy, peptide vaccination, and targeted treatments for different melanoma stages.

hollye
Télécharger la présentation

Melanoma Therapeutic Studies at University Hospital Heidelberg

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Therapiestudien beim Melanom am Hauttumorzentrum der Univ.-Hautklinik Heidelberg im Nationalen Centrum für Tumorerkrankungen (NCT) Ansprechpartner: Dr. med. Jessica C. Hassel Oberärztin Tel: 06221 – 56-38503 jessica.hassel@med.uni- heidelberg.de Stadium II pT > 2,0 mm Low-dose IFN Therapie Aktuell keine Studien tumorfrei (nach OP) Multiferon (ADO) Einschluss: StadiumIIIB+C (2-10 Met) Ausschluss: SH-MM, Uvea-MM, Herzerkr, Autoimmunerkr vor OP (R0 erreichbar) Stadium III LK Metastasen RAB38/NY-MEL-1 Peptid Vakzinierung (Jäger) Einschluss: Stadium III o IV , HLA-A2+, RAB38/Ny-MEL-1+ (Biopsie) Ausschluss: Immunsuppression - Zur Zeit pausiert - tumorfrei (nach OP) High oder Low-dose IFN Therapie Aktuell keine Studien Stadium IV Fernmetastasen E7080-206 (Eisai) Einschluss: Stadium IIIunres/IV, 1-2 Vorther, BRAF-Mut+, BRAF-Inhib. Vorther Ausschluss: Z.n. anti-VEGF-Ther, Uvea- MM, Hirnmet, QT-Verlängerung, Gerinnungsstörung Second- line mit Tumorlast (nach OP) E7080-702 (Eisai-Max) Einschluss: Stadium IV, behandelte Hirnmet Ausschluss: Uvea- MM, unkontrollierte art. Hypertonie Firstline NY-ESO Ipilimumab (Jäger) Einschluss: spontane Immunantwort gegen NY-ESO1 Ausschluss: ECOG >1, KI gg Ipi Chemotherapie nach TCA vs DTIC (ChemosensMM-ADO) Einschluss:Firstline Stadium IV, max 1 Vorther (ausser Chemo), auch MUP, SH-MM Ausschluss: ZNS-Met, Uvea-MM Ipilimumab Multibasket (ADO) Einschluss: Uvea-MM, auch Hirnmet Ausschluss: aktive Autoimmunerkr. Tasigna (TEAM-Novartis) Einschluss: Stadium IIIc o IV, c-kit Mutation Ausschluss: Herzinsuffizienz BRAF-EAP (Roche) Einschluss: IV, > 2ndline, BRAFV600+, Ausschluss: symptomat. ZNS-Met, schwere Herzerkr, QT >450msec Version 10/2011

More Related